1Kalish LH, Kwong RA, Cole IE, et al. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine klnase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines[ J]. Clin Cancer Res, 2004,10(22) :7764 -7774. 被引量：1
2Matheny KE, Barbieri CE, Sniezek JC, et al. Inhibition of epidermal growth factor receptor signaling decrease p63 expression in head and neck squamous carcinoma cell[J]. Laryngoscope, 2003, 113(6) :936 -939. 被引量：1
3Shlntani S, Li C, Mihara M, et al. Gefitinib(‘Iressa' ,ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up - regulatesp27KIPI and induces arrest in oral squamous cell carcinoma cell lines[J]. Oral.Oncol, 2004,40(1) :43 -51. 被引量：1
4Hambek M, Baghi M, Strebhard K, et al. Reduction of cisplatin dosage by ZD1839[J]. Anticancer Res, 2005,25(6B) :3985 - 3988. 被引量：1
5Shintani S, Kiyota A, Mihara M, et al. Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 (‘Iressa' ), a selective epidermal growth factor receptor tyrosine kinase inhibitor [J]. Am J Clin Oncol, 2003,26(50) : 150 -156. 被引量：1
6Cohen EE, Rosen F, Stadler WM, et al. Phase Ⅱ trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck [ J ]. J Clin Oncol, 2003,21 (10) : 1980 - 1987. 被引量：1
7Cohen EE, Kane MA, Liast MA, et al. Phase Ⅱ trial of Gefitinib 250rag daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck[ J]. Clin Cancer Res, 2005, 11(23) :8418 -8424. 被引量：1
8Belon J, Irigoyen A, Redriguez I, et al. Preliminary results of a phase Ⅱ study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous - cell carcinoma of the head and neck [ J ]. J Clin Oncol, 2005,23: 515. 被引量：1
9Doss HH, Greco FA, Meluch AA, et al. Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/ gefitinib for patients with locally advanced squamous carcinoma of the head and neck : A phase Ⅰ/Ⅱ trial of the Minnie Pearl Cancer Research Network[ J]. J Clin Oncol,2006,24:5543. 被引量：1
10Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck [ J ]. J Clin Oncol, 2004,22:77 - 85. 被引量：1
9Shih C,Tcichcr BA.Cryptophycins :a novel class of potent antimitoticantitumor dcpsipeptides[J]. Curr Pharm Des, 2001,7(13) : 1259-1276. 被引量：1
10Cohen EE, Rosen F, Stadler WM, et al. Phase Ⅱ trial of ZD18392 in recurrent or metastatic squamous cell carcinoma of the head and neck[J]. J Clin Oncol, 2003,21(10) : 1980-1987. 被引量：1
